Skip to content
Review Open access

Three-dimensional in vitro models for assessing temozolomide sensitivity in glioblastoma.

Oct 2026 · Frontiers in Neuroscience · Vol 20, pp. 1901494 · 0 citations · 203 references
Medicine

TL;DR

Three-dimensional culture systems, including tumor spheroids and organoids, are emphasized, which more effectively recapitulate tumor architecture, cell-cell interactions, and drug penetration gradients than conventional two-dimensional models.

Abstract

IDH-wildtype glioblastoma, or glioblastoma multiforme (GBM), is the most aggressive primary malignancy of the central nervous system. It is characterized by marked invasiveness, intratumoral heterogeneity, and high recurrence rates, largely driven by intrinsic and acquired resistance to standard temozolomide (TMZ) therapy. TMZ is an oral alkylating agent that methylates nitrogenous bases, mainly forming O6-methylguanine (O6-meG) lesions, the main cytotoxic and mutagenic events responsible for its antitumor effects. This review first characterizes gliomas and the mechanism of action of the main GBM treatment drug (TMZ), then critically examines in vitro cell culture models investigating these mechanisms. This review emphasizes the development and application of three-dimensional (3D) culture systems, including tumor spheroids and organoids, which more effectively recapitulate tumor architecture, cell-cell interactions, and drug penetration gradients than conventional two-dimensional models. This review discusses the strengths and limitations of these models and their translational relevance to modeling TMZ sensitivity and resistance in GBM.

Read PDF

Similar papers

Review Open access Sep 2026

Translational Insights and Clinical Relevance of Glioblastoma 3D In Vitro Models.

Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, highlighting the urgent need for experimental models that can faithfully recapitulate its complex biology. In vitro models are essential tools for investigating GBM biology and for preclinical drug development. Conventional two-...

Claudia Orlanno, E. Lamparelli, Adamo Lancellotti et al. · 0 citations
Open access Oct 2026

Indole analogs and the aryl sulfonamide AqB011 potently restrain the invasiveness of glioblastoma cells, as determined in ex vivo xenograft tissue slice co-cultures (XTCCs)

Glioblastomas (GBMs) are highly invasive and heterogeneous in nature which strongly contributes to poor survival of patients, averaging 15 months after diagnosis. With little treatment options being available in particular for addressing GBM invasiveness, there is a high need for supplementary therapies in addition to...

Kim K. Wagner, A. J. Yool, Rohan A. Davis et al. · 0 citations
Open access Sep 2026

Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms

Introduction Glioblastoma remains one of the most treatment-resistant cancers, and temozolomide (TMZ) resistance is a central barrier to durable clinical response. Inhibition of exportin-1 (XPO1) by selinexor has emerged as a promising strategy to overcome resistance in solid tumors; however, its ability to sensitize T...

Beyza Ozturk, A. Çelebi, D. Kılıç et al. · 0 citations
Open access Sep 2026

Targeting Nectin-4 sensitizes glioblastoma to temozolomide

Background Temozolomide (TMZ) remains the first-line chemotherapeutic agent for glioblastoma (GBM), but its clinical efficacy is often limited by acquired resistance. This study aimed to investigate whether nectin-4 could serve as a target to sensitize GBM cells to TMZ and to determine whether resveratrol enhances TMZ...

Xiao-Guang Zhang, Hua Wang, Jin-Ning Song · 0 citations
Open access Oct 2026

Insulin and Temozolomide effects in a glioblastoma multiforme cell model (U-251)

Glioblastoma multiforme (GBM) is an astrocytoma classified among the most aggressive brain tumors. Currently considered incurable, patients have a median survival of 15 months after diagnosis. Treatment typically involves tumor resection followed by radiotherapy and chemotherapy. Temozolomide is the most commonly used...

Ayşe Mine Yılmaz, Burak Kızılca, Zafer Alparslan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.